JP2014534169A - Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置 - Google Patents
Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置 Download PDFInfo
- Publication number
- JP2014534169A JP2014534169A JP2014531256A JP2014531256A JP2014534169A JP 2014534169 A JP2014534169 A JP 2014534169A JP 2014531256 A JP2014531256 A JP 2014531256A JP 2014531256 A JP2014531256 A JP 2014531256A JP 2014534169 A JP2014534169 A JP 2014534169A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- arrangement
- seq
- infection
- homologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 110
- 238000009739 binding Methods 0.000 title claims abstract description 29
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 10
- 206010040047 Sepsis Diseases 0.000 claims description 10
- 229960003085 meticillin Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 208000031729 Bacteremia Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000037815 bloodstream infection Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 208000004396 mastitis Diseases 0.000 claims description 5
- 206010056559 Graft infection Diseases 0.000 claims description 4
- 206010061308 Neonatal infection Diseases 0.000 claims description 4
- 206010031252 Osteomyelitis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010062255 Soft tissue infection Diseases 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 description 25
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 230000008782 phagocytosis Effects 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 206010057249 Phagocytosis Diseases 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 210000001539 phagocyte Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000031462 Bovine Mastitis Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000004817 opsonic phagocytosis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182598.0 | 2011-09-23 | ||
| EP11182598 | 2011-09-23 | ||
| US201161545763P | 2011-10-11 | 2011-10-11 | |
| US61/545,763 | 2011-10-11 | ||
| PCT/EP2012/068703 WO2013041707A1 (en) | 2011-09-23 | 2012-09-21 | Peptide or arrangement of peptides forming a staphylococcus aureus epitope binding site |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014534169A true JP2014534169A (ja) | 2014-12-18 |
| JP2014534169A5 JP2014534169A5 (enExample) | 2017-02-16 |
Family
ID=47913924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014531256A Ceased JP2014534169A (ja) | 2011-09-23 | 2012-09-21 | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9422365B2 (enExample) |
| EP (1) | EP2758431A1 (enExample) |
| JP (1) | JP2014534169A (enExample) |
| CN (1) | CN103857697A (enExample) |
| AU (1) | AU2012311428A1 (enExample) |
| WO (1) | WO2013041707A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2616728T3 (es) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedimientos y composiciones para facilitar la regeneración |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| US9944694B2 (en) * | 2013-12-13 | 2018-04-17 | Rijksuniversiteit Groningen | Antibodies against Staphylococcus aureus and uses therof |
| IL251210B2 (en) | 2014-09-19 | 2023-12-01 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| CN109071675A (zh) | 2016-02-19 | 2018-12-21 | Siwa有限公司 | 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物 |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10858449B1 (en) * | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10995151B1 (en) * | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
| CN119431528B (zh) * | 2024-10-28 | 2025-10-14 | 中国人民解放军陆军军医大学 | 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004534000A (ja) * | 2001-01-26 | 2004-11-11 | インヒビテックス インコーポレーテッド | Ｃｌｆａタンパク質に対するモノクローナル抗体および感染症を処置または予防することにおける使用の方法 |
| JP2009031009A (ja) * | 2007-07-24 | 2009-02-12 | St Marianna Univ School Of Medicine | 黄色ブドウ球菌の検出または同定方法および検出キット |
| WO2010133600A1 (en) * | 2009-05-18 | 2010-11-25 | Julius-Maximilians-Universität Würzburg | Antibodies or fragments thereof directed against a staphylococcus aureus epitope of isaa or isab |
-
2012
- 2012-09-21 WO PCT/EP2012/068703 patent/WO2013041707A1/en not_active Ceased
- 2012-09-21 AU AU2012311428A patent/AU2012311428A1/en not_active Abandoned
- 2012-09-21 EP EP12759781.3A patent/EP2758431A1/en not_active Withdrawn
- 2012-09-21 CN CN201280046452.2A patent/CN103857697A/zh active Pending
- 2012-09-21 US US14/346,435 patent/US9422365B2/en not_active Expired - Fee Related
- 2012-09-21 JP JP2014531256A patent/JP2014534169A/ja not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004534000A (ja) * | 2001-01-26 | 2004-11-11 | インヒビテックス インコーポレーテッド | Ｃｌｆａタンパク質に対するモノクローナル抗体および感染症を処置または予防することにおける使用の方法 |
| JP2009031009A (ja) * | 2007-07-24 | 2009-02-12 | St Marianna Univ School Of Medicine | 黄色ブドウ球菌の検出または同定方法および検出キット |
| WO2010133600A1 (en) * | 2009-05-18 | 2010-11-25 | Julius-Maximilians-Universität Würzburg | Antibodies or fragments thereof directed against a staphylococcus aureus epitope of isaa or isab |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012311428A1 (en) | 2014-04-24 |
| CN103857697A (zh) | 2014-06-11 |
| WO2013041707A1 (en) | 2013-03-28 |
| EP2758431A1 (en) | 2014-07-30 |
| US9422365B2 (en) | 2016-08-23 |
| US20140234339A1 (en) | 2014-08-21 |
| AU2012311428A2 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534169A (ja) | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置 | |
| CN103906535B (zh) | 与葡萄球菌蛋白a的抗体相关的组合物和方法 | |
| JP6192294B2 (ja) | グラム陽性菌特異的結合化合物 | |
| US9658230B2 (en) | Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB | |
| US7128912B2 (en) | Fibronectin binding protein compositions and methods of use | |
| JP2011046705A (ja) | 抗ラクトンシグナル分子抗体または抗ラクトン由来シグナル分子抗体による感染性細菌症の治療のための方法 | |
| JP6251730B2 (ja) | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 | |
| JP2010509937A (ja) | プロテインａ選択性を有する抗体 | |
| JP2010013454A (ja) | グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体 | |
| Boero et al. | Natural human immunity against staphylococcal protein A relies on effector functions triggered by IgG3 | |
| CN120943954A (zh) | 抗金黄色葡萄球菌IsdB抗体的制备及其应用 | |
| US10981979B2 (en) | Human monoclonal antibodies to Staphylococcus aureus lukab toxin | |
| TW202417478A (zh) | 用於治療支氣管擴張的抗PcrV和Psl雙特異性藥物 | |
| US11992520B2 (en) | Human monoclonal antibodies to Staphylococcal aureus Isd proteins and uses thereof | |
| JP2018512866A (ja) | Ｓ．アウレウスの免疫グロブリン結合タンパク質に対して向けられた抗体 | |
| Bennett | Molecular Basis for Antibody-mediated Immunity against Iron-Binding Proteins in Staphylococcus aureus | |
| JPH06339391A (ja) | シュウドモナス・エルギノサ感染の治療及び診断用抗体 | |
| Lenkey | Using phage display to select peptides binding to type 8 capsular polysaccharide of Staphylococcus aureus | |
| HK1197654A (en) | Compositions and methods related to antibodies to staphylococcal protein a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150831 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170104 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170104 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170629 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20171026 |